Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about TYRA, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Dabogratinib (TYRA-300) | Low Grade Upper Tract Urothelial Carcinoma | Phase 2 · NCT07265947 | Recruiting |
| Phase 1 Part A - dose escalation TYRA-200 taken… | Locally Advanced Cholangiocarcinoma | Phase 1 · NCT06160752 | Active not recruiting |
| Phase 1 Part B - dose expansion TYRA-200 taken… | Locally Advanced Cholangiocarcinoma | Phase 1 · NCT06160752 | Active not recruiting |
| FGFR3/4 Inhibitor TYRA-430 | Metastatic Hepatocellular Carcinoma | Phase 1 · NCT06915753 | Recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
TYRA holds $700.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $31.6M/quarter from operations, an estimated runway of 66.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 24 · Moderate
Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities as of September 30, 2026 will be sufficient to fund our operating expenses and capital expenditures through 2030.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TYRA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. Director, 10% owner · +11.63M options |
Insider | 14,130,492 | 20.45% | 2026-09-15 |
| FMR LLC | Institution (13G, 5%+) | 7,747,648 | 11.22% | 2026-03-31 |
| BVF PARTNERS L P/IL | Institution (13G, 5%+) | 4,215,886 | 6.10% | 2026-09-14 |
| JANUS HENDERSON GROUP PLC | Institution (13G, 5%+) | 3,890,589 | 5.63% | 2026-03-31 |
| Robert J More Director · +13,160 options |
Insider | 3,823,425 | 5.53% | 2025-12-19 |
| Dapice Joshua J. | 5%+ holder (13G) | 3,580,818 | 5.18% | 2026-03-31 |
| Nextech VI Oncology SCSp | 5%+ holder (13G) | 3,553,585 | 5.14% | 2026-06-30 |
| Paradigm BioCapital Advisors LP | 5%+ holder (13G) | 3,473,453 | 5.03% | 2026-09-10 |
| Todd Harris President and CEO, Director · +835,000 options |
Insider | 1,438,495 | 2.08% | 2026-09-15 |
| Daniel Bensen Chief Discovery Officer · +170,000 options |
Insider | 146,981 | 0.21% | 2026-02-12 |
| Alan Fuhrman Chief Financial Officer · +237,000 options |
Insider | 37,115 | 0.05% | 2026-09-15 |
| Gilla Kaplan Director |
Insider | 28,231 | 0.04% | 2026-03-25 |
Share count 69,082,747 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TYRA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →